TNSN08062A1 - Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin - Google Patents

Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin

Info

Publication number
TNSN08062A1
TNSN08062A1 TNP2008000062A TNSN08062A TNSN08062A1 TN SN08062 A1 TNSN08062 A1 TN SN08062A1 TN P2008000062 A TNP2008000062 A TN P2008000062A TN SN08062 A TNSN08062 A TN SN08062A TN SN08062 A1 TNSN08062 A1 TN SN08062A1
Authority
TN
Tunisia
Prior art keywords
butoxyiminomethylcamptothecin
topoisomerase
inhibitor
tert
microparticle compositions
Prior art date
Application number
TNP2008000062A
Inventor
Wolfgang Wirth
Oskar Kalb
Walter Stebler
Agnes Taillardat
Isabel Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN08062(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TNSN08062A1 publication Critical patent/TNSN08062A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to microparticle pharmaceutical compositions in which the active agent is a topoisomerase I inhibitor, in particular, 7-f-butoxyiminomethylcamptothecin, that is useful for the treatment and prevention of proliferative diseases including cancer.
TNP2008000062A 2005-08-10 2008-02-08 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin TNSN08062A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10
PCT/EP2006/065160 WO2007017514A1 (en) 2005-08-10 2006-08-08 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin

Publications (1)

Publication Number Publication Date
TNSN08062A1 true TNSN08062A1 (en) 2009-07-14

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000062A TNSN08062A1 (en) 2005-08-10 2008-02-08 Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin

Country Status (20)

Country Link
EP (1) EP1915132A1 (en)
JP (1) JP2009504616A (en)
KR (1) KR20080034989A (en)
CN (1) CN101287448A (en)
AR (1) AR055602A1 (en)
AU (1) AU2006277879A1 (en)
BR (1) BRPI0614757A2 (en)
CA (1) CA2618084A1 (en)
EC (1) ECSP088166A (en)
GT (1) GT200600364A (en)
IL (1) IL189076A0 (en)
MA (1) MA29735B1 (en)
MX (1) MX2008001965A (en)
NO (1) NO20081213L (en)
PE (1) PE20070232A1 (en)
RU (1) RU2008108885A (en)
TN (1) TNSN08062A1 (en)
TW (1) TW200800195A (en)
WO (1) WO2007017514A1 (en)
ZA (1) ZA200800726B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (en) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE OR ALCANOYL L-CARNITINE USABLE CATIONIC COMELIPIDS FOR INTRACELLULAR PLACING OF COMPOUNDS
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (en) * 2004-11-19 2006-06-19 ORGANIC COMPOUNDS

Also Published As

Publication number Publication date
PE20070232A1 (en) 2007-04-09
JP2009504616A (en) 2009-02-05
EP1915132A1 (en) 2008-04-30
AR055602A1 (en) 2007-08-29
KR20080034989A (en) 2008-04-22
MX2008001965A (en) 2008-03-26
MA29735B1 (en) 2008-09-01
CA2618084A1 (en) 2007-02-15
ZA200800726B (en) 2009-08-26
TW200800195A (en) 2008-01-01
WO2007017514A1 (en) 2007-02-15
IL189076A0 (en) 2008-08-07
CN101287448A (en) 2008-10-15
BRPI0614757A2 (en) 2011-04-12
NO20081213L (en) 2008-05-13
ECSP088166A (en) 2008-03-26
AU2006277879A1 (en) 2007-02-15
GT200600364A (en) 2007-03-19
RU2008108885A (en) 2009-09-20

Similar Documents

Publication Publication Date Title
MY148647A (en) Pharmaceutical compositions comprising a camtothecin derivative
MX2009006704A (en) New compounds.
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
MX2007014920A (en) Combination therapy comprising diaryl ureas for treating diseases.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG178873A1 (en) Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors
MX2009000285A (en) Substituted piperidines that increase p53 activity and the uses thereof.
MX363435B (en) Topical formulations having enhanced bioavailability.
IL197080A0 (en) Pyrimidone compounds as gsk-3 inhibitors
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007121088A3 (en) Combinations of therapeutic agents for treating cancer
TW200700071A (en) Novel use
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
WO2007017513A3 (en) Formulations for 7-(t-butoxy)iminomethyl camptothecin
TW200730190A (en) New combination to treat liver fibrosis
WO2006102375A3 (en) Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
WO2007130501A3 (en) Combination therapy for treatment of cancer
WO2006128740A3 (en) Anti-vascular methods and therapies employing lysyl oxidase inhibitors
MX2008008470A (en) Novel pyrrole derivatives with histone deacetylase inhibitor activity.
WO2009148600A3 (en) Deuterated lysine-based compounds
EP2124554A4 (en) Compositions and methods for the treatment of cancer
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
TNSN08062A1 (en) Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin